Target
$179.32 → $179.33
Current stock research snapshot · 7/19/26 40 days old
RGENRepligen
Investment conviction●●○○○2 of 5 · current snapshot
Research target$179.33Current stock price target
Investment thesis statusSTRENGTHENEDLast reviewed 7/19/26
Market cap$8.31BSnapshot value · 7/19/26
Research history
See all RGEN changes ↗What changed
Target
$179.31 → $179.32
Bottleneck supplier of upstream bioprocessing consumables and systems; Q2 beat and BioLife acquisition reinforce demand for biologics manufacturing automation.
FY26 raised guidance; BioLife Solutions synergies; new OEM partnerships in China; biopharma capacity expansion cycle.
Sustained biopharma capex slowdown, consumables demand deterioration, or China OEM/local-manufacturing execution failure that prevents margin-accretive growth.
GREEN / no material signal on 2026-07-16 scan
Snapshot · 7/19/26🟡 Mixed · ins-$1.7M · 13F 20+/5-×0.5 · short↑0.44
Snapshot · 7/19/26